Dextera Biosciences is developing a new category of drugs, Synthetic D-Proteins, to overcome the limitations of current drug modalities. Synthetic D-Proteins exhibit antibody-like specificity to a single therapeutic target but with the broad distribution of small molecules, all while being otherwise “invisible” to the rest of the body. The consequences are that we can deliver sustained antibody-like activity specifically to interstitial targets, enable oral delivery with complete metabolic stability, and extend therapeutic durability with no immunogenicity. We are focusing on debilitating diseases where significant unmet need remains due to the limitations of current drugs.
| Target | Indication(s) | Route | Hit Discovery Lead Optimization IND Enabling Phase 1a,b |
|---|---|---|---|
| Payload Conjugate Oncology | |||
| HEr2 | Multiple |  |
|
| Nectin-4 | Multiple | |
|
| Immuno-oncology | |||
| PD-1 x VEGF | Multiple | |
|
| Immunologoy & Inflammation (I&I) | |||
| TNF | IBD, RA, PSO |  |
|
| IL-23 p19 | IBD, PSO | |
|
| IL-17 A/F | PSO, HS, AxSpA | |
|